Spigel D, et al. Impower110: interim overall survival (OS) analysis of a phase 3 study of atezolizumab (atezo) versus platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC. ESMO Congress 2019, abstract LBA78.
Onderzoek naar cutane T-cellen leidt tot paradigmaverschuiving voor graft-versus-hostziekte
okt 2021 | Stamceltransplantatie